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Summary Urinary polyamine (UPA) excretion patterns were measured in 39 patients with clinically evaluable
epithelial ovarian cancer immediately before they were treated with a cycle ofchemotherapy and 24-48 h after
chemotherapy to ascertain if changes in UPA excretion patterns correlated with eventual response to
treatment. Almost all of the 19 patients who responded to chemotherapy had a rise in the excretion of all
UPA fractions after treatment while most patients with chemoresistant cancer showed only an increase in the
excretion of the putrescine and spermine fractions. However, a two-fold increase in excretion of the spermidine
fractions occurred exclusively in patients who would eventually respond to chemotherapy. This phenomenon
was not seen in patients with chemoresistant cancer. If, 48 h after chemotherapy, a patient with epithelial
ovarian cancer does not show at least a doubling of the urinary levels of spermidine, acetylspermidine or total
polyamine excretion that chemotherapy should be stopped since it is unlikely to be effective.
Most patients with advanced epithelial ovarian cancer are
treated with chemotherapy. Cisplatinum-containing regimens
are the most active but are also the most toxic (Richardson
et al., 1985). For the individual patient the value of being
able to predict response early during a course of chemo-
therapy would be in preventing unnecessary toxicity because
ineffective therapy would be discontinued. In addition
second-line therapy might be more effective if it could be
introduced before it was apparent by clinical or radiological
examination that first-line treatment had failed.
The polyamines are low molecular weight cationic mole-
cules which play important roles in cell proliferation and
synthesis of DNA. There have been several reports of
elevated urinary polyamine (UPA) levels in patients with a
wide variety of cancers (Woo et al., 1983; Horn et al., 1984;
Kingsnorth & Wallace, 1985) and we have reported pre-
viously on polyamine excretion patterns in patients with
epithelial ovarian cancer (Lawton et al., 1989a).
In 1977 Durie et al. showed that, during chemotherapy
treatment, the level of one UPA, spermidine, rose, and that a
greater than two-fold increase after chemotherapy correlated
well with an eventual clinical response. This paper referred to
a wide variety of haematological and solid malignancies but
there are no data relating to patients with ovarian cancer.
Patients with epithelial ovarian cancer treated in West
Midlands Ovarian Cancer Group protocols over an 18
month period had pre- and post-treatment UPA levels
measured so that acute changes with therapy and their value
in predicting eventual response might be assessed. This report
details the results of this study.
Materials and methods
Thirty-nine previously untreated patients with biopsy proven
epithelial ovarian cancer FIGO stage III or IV, provided a
25 ml urine sample immediately before their first (24 patients)
or second (15 patients) cycle of treatment and a second
sample 48 h later. All urine samples were provided at the
same time of day and there were no overnight samples. All
patients had bulky residual disease after primary laparotomy,
had clinically evaluable pelvic or abdominal masses and were
treated with one of two cisplatinum-containing combination
regimens details of which have been reported previously
(Lawton et al., 1989b). Response to chemotherapy was
assessed by one of two authors (FGL or GB) after the third
or fourth cycle, that is 6-10 weeks after UPA measurement,
using standard criteria (WHO, 1979). Nineteen patients re-
sponded to treatment (complete or partial response) and 20
had either static or progressive disease.
The paired urine samples were assessed for free putrescine,
spermidine and spermine levels as well as their three
acetylated conjugates and the total UPA excretion using a
derivatisation technique and high performance liquid
chromatography. Briefly, after ion-exchange chromato-
graphy, each urine sample was divided into two aliquots. One
aliquot was hydrolysed by heating it for 18 h at 105°C with
0.5 ml N HCI. The polyamines in each of the two urine
samples per patient were derivatised using 4-fluoro-3-nitro-
benzo trifluoride using the method of Spragg and Hutchings
(1983), extracted from the mixture and redissolved in
0.125 ml ethanol. The derivatised polyamines were separated
by HPLC and detected by ultraviolet fluorimetry and quan-
tified by comparing their peak height with that of a known
concentration of an internal standard, 1,8-diamineoctane.
Total polyamine levels were measured in the hydrolysed urine
sample and free levels in the non-hydrolysed sample.
Acetylated levels were therefore calculated by subtraction.
Polyamine levels were expressed as microgram UPA per
milligram urinary creatinine. The intra-assay variation for
free putrescine, spermidine and spermine was 15%, 26% and
25% respectively, for their acetylated derivatives 19%, 26%
and 20% and 10% for total polyamine concentration (Law-
ton, 1987). Between-batch variation was below 10%. Dupli-
cate urine samples, 10% in each batch, were included in each
assay to ensure assay reproducability. Details of mean
urinary polyamine excretion levels and excretion patterns for
various patient subgroups in this study population have been
published previously (Lawton et al., 1989a).
For each urine sample and each polyamine fraction the
post-treatment level (UPA2) was compared with the pre-
treatment level (UPAI) and the ratio UPA2/UPAI calculat-
ed. A value of greater than 1 would indicate a rise in UPA
level with treatment and a value of greater than 2 would
indicate at least a doubling in polyamine excretion with
therapy. These ratios were correlated with the response to
treatment.
Results
Patients with responding disease (n = 19)
Fifteen patients (79%) had a rise in all UPA fractions follow-
ing treatment and total UPA excretion was raised after treat-
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ment for all 19 patients. In at least 52% of patients (range
52-79%), depending on the specified polyamine, post-treat-
ment UPA levels were twice the pre-treatment result. Four
patients, all with partial response to treatment and with a
response duration of 4 months or less accounted for all of
the instances of falling UPA excretion with treatment. (See
Table I.)
Patients with static or progressive disease (n = 20)
A doubling in UPA excretion after chemotherapy was seen
only in between 15 and 35% of patients who had no re-
sponse to chemotherapy and no patient with an eventual
response to chemotherapy demonstrated more than a two-
fold increase in either spermidine or acetylspermidine excre-
tion after chemotherapy. No differences were seen between
urinary polyamine patterns in samples obtained after the first
cycle when compared with those obtained after the second
cycle. (See Table I.)
Discussion
UPA levels in patients with EOC vary with tumour status
but, with a sensitivity of only around 40% and a wide
variation in normal levels, UPA excretion patterns, like many
other tumour associated substances, are poor markers in
patients with ovarian cancer (Lawton et al., 1989a). How-
ever, Durie et al. suggested that UPA levels reflected disease
activity as well as tumour burden and so might be useful as a
marker of response to treatment. They showed that for
patients with chemosensitive tumours, there would be at least
a 2-fold increase in urinary spermidine excretion after treat-
ment while patients with non-responding tumours showed
little change in spermidine excretion with therapy. However,
half of the patients in their study group had haematological
malignancies and none of the patients with solid tumours
had epithelial ovarian cancer. In addition their patients were
treated with a variety of regimens and these facts make it
difficult to draw firm conclusions as to a potential role for
using UPA excretion to predict response to treatment in
patients with epithelial ovarian cancer. Therefore we were
encouraged to test these hypotheses in a well defined group
of patients with EOC undergoining first-line cisplatinum con-
taining combination chemotherapy.
We have shown that, in general, a doubling in urinary free
spermidine or acetylspermidine levels, within 48 h of a cycle
of chemotherapy, is a phenomenon demonstrated exclusively
by chemosensitive tumours. Eighteen of nineteen patients
with a rise in acetylspermidine following treatment responded
to therapy giving a predicitive value of a positive test of
95%. The predictive value for the other polyamine fractions
varied from 44% for free putrescine to 85% for free sper-
midine. This result would be expected according to Russell's
hypothesis that spermidine excretion is a marker of tumour
cell loss while the other UPAs reflect tumour cell replication
(Russell et al., 1975).
UPA excretion patterns can therefore be used to limit
treatment associated toxicity, but there are also preliminary
data to suggest that predicting the eventual response to
therapy may also improve patient survival. In a study of
previously untreated patients with ovarian cancer the res-
ponse rate and median survival for patients treated with
drugs selected on the basis of an in vitro sensitivity assay
were significantly superior than for those treated with a
standard cisplatin/adriamycin/cyclophosphamide regimen
(Welander, 1987).
An in vivo predictive test based on acute changes in UPA
excretion may have some advantages over other assays. First,
the potential effect of chemotherapy can be assessed rapidly
and over a single treatment cycle and second, unlike other in
vitro assays, tumour biopsies are not required and the prob-
lems of cell culture for drug sensitivity testing are avoided
(Bradley et al., 1984).
The result of our study would suggest that, if 48 h after
chemotherapy, a patient with epithelial ovarian cancer does
not show at least doubling of the urinary levels of sper-
midine, acetylspermidine or total polyamines, that
chemotherapy should be stopped since it is unlikely to be
effective.
This work was supported by the Cancer Research Campaign and the
West Midlands Regional Health Authority.
Table I Changes in UPA excretion patterns with chemotherapy
Patients responding to Patients resistant to
treatment(n = 19) treatment (n = 20)
Median ratio No. ofpatients with Median ratio No. ofpatients with
UPA2/UPAJ with at least a x 2 UPA2/UPA1 with at least a x 2
treatment increase in UPA treatment increase in UPA
UPA (range) with treatment (range) with treatment
Put 2.48 (0.17-33) 10 (53%) 1.33 (0.07-6.3) 7 (35%)
Spd 2.65 (0.3-9.8) 15 (79%) 0.58 (0.08-1.91) 0
Spm 3.5 (0.28-8.67) 14 (74%) 1.08 (0.01-8.02) 5 (25%)
Acput 2.07 (0.57-1.39) 10 (53%) 1.31 (0.23-3.51) 3 (15%)
Acspd 4.76 (0.84-6.82) 13 (68%) 0.51 (0.08-0.96) 0
Acspm 2.21 (0.14-7.51) 10 (53%) 1.17 (0.1-2.5) 4 (20%)
Totpa 2.25 (1.28-9.53) 13 (68%) 0.89 (0.41-2.63) 3 (15%)
References
BRADLEY, E.C., ISSEL, B.F. & HELLMAN, R. (1984). The human
tumor colony forming chemosensitivity assay: a biological and
clinical review. Invest. New Drugs, 2, 59.
DURIE, B.G.M., SALMON, S.E. & RUSSELL, D.H. (1977). Polyamines
as markers of response and disease activity in cancer
chemotherapy. Cancer Res., 37, 214.
HORN, Y., BEAL, S.L., WALACH, N., LUBICH, W.P., SPIGEL, L. &
MARTON, L.J. (1984). Relationship of urinary polyamines to
tumor activity and tumor volume in patients. Cancer Res., 44,
4675.
KINGSNORTH, A.N. & WALLACE, H.M. (1985). Elevation of
monoacetylated polyamines in human breast cancers. Eur. J.
Cancer Clin. Oncol., 21, 1057.
LAWTON, F.G. (1987). An assessment of the clinical role of urinary
polyamine measurement in patients with epithelial ovarian
cancer. MD Thesis, University of Manchester.
LAWTON, F.G., GRIFFIN, M., SLACK, J.A. & BLACKLEDGE, G.
(1989a). Urinary polyamine excretion patterns in patients with
epithelial ovarian cancer. Gynecol. Obstet. Invest., 28, 212.
LAWTON, F.G., REDMAN, C.W.E., LUESLEY, D.M., CHAN, K.K. &
BLACKLEDGE, G. (1989b). Neoadjuvant (cytoreductive)
chemotherapy combined with intervention debulking surgery in
advanced, unresected epithelial ovarian cancer. Obstet. Gynecol.,
73, 61.694 F.G. LAWTON et al.
RICHARDSON, G.S., SCULLY, R.E., NIKRUI, N. & NELSON, J.H. Jr
(1985). Common epithelial cancer of the ovary (second of two
parts). N. Engl. J. Med., 312, 474.
RUSSELL, D.H., DURIE, B.G.M. & SALMON, S.E. (1975). Polyamines
as predictors of success and failure in cancer chemotherapy.
Lancet, fi, 797.
SPRAGG, B.P. & HUTCHINGS, A.D. (1983). High performance liquid
chromatographic determination of putrescine, spermidine and
spermine after derivatisation with 4-fluoro-3-nitrobenzotri-
fluoride. J. Chromatogr., 258, 289.
WELANDER, C.E. (1987). Predicting response to chemotherapy with
a clonogenic assay. In Ovarian Cancer - the Way Ahead, Sharp,
F. & Soutter, W.P. (eds). p. 175. Royal College of Obstetricians
and Gynaecologists: London.
WHO (1979). Handbook for Reporting Results of Cancer Treatment.
WHO Offset Publications, No. 8: Geneva.
WOO, K.B., WAALKES, P.T., ABELOFF, M.D., LENHARD, R.E. Jr,
GEHRKE, C.W. & KUO, K.C. (1983). Urinary polyamines for
evaluating the course of disease for patients with small cell
carcinoma of the lung. Cancer, 52, 1684.